Further studies should focus on assessing the effects of both single and prolonged TNFR2 agonist stimulation at different stages of the remyelination process and in models where remyelination fails to critically evaluate the therapeutic relevance for MS. The gene discussed is TNFRSF1B; the disease is myeloid sarcoma.